SHELLAC
SHELLAC is a cosmetic ingredient classified as Binding. Also known as CAS 9000-59-3. No specific regulations have been found across 26 tracked markets.
Also Known As
- CAS Number
- 9000-59-3
Market Overview — 29 Markets
Detailed Regulations
EuropeNo restrictions
No specific restrictions for SHELLAC in European Union, United Kingdom.
AmericasNo restrictions
No specific restrictions for SHELLAC in United States, California, Maryland, Washington, Canada, Brazil.
East Asia & OceaniaNo restrictions
No specific restrictions for SHELLAC in South Korea, Japan, Taiwan, Australia.
ASEANNo restrictions
No specific restrictions for SHELLAC in Singapore, Malaysia, Thailand, Indonesia, Vietnam, Philippines.
GCCNo restrictions
No specific restrictions for SHELLAC in UAE, Saudi Arabia, Qatar, Oman, Kuwait, Bahrain.
EAEUNo restrictions
No specific restrictions for SHELLAC in Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan.
Frequently Asked Questions
Is SHELLAC banned in any country?
SHELLAC is not banned in any of the 26 markets tracked by Formpli. However, it may be subject to restrictions or conditions of use in some markets.
What are the restrictions on SHELLAC in cosmetics?
SHELLAC has no specific restrictions in any of the 26 markets tracked by Formpli. It can generally be used in cosmetic formulations, subject to local general cosmetic regulations.
Can I use SHELLAC in cosmetics?
SHELLAC has no specific regulations in any of the 26 markets tracked by Formpli. Use our free screening tool to verify your complete formula before exporting.
Screen SHELLAC with your full formula
Paste your entire ingredient list and get a compliance report across 26 markets — free, no signup.
Check Ingredients FreeThis information is for reference only and does not constitute legal or regulatory advice. Regulations change — always verify with official sources and consult a regulatory specialist before exporting cosmetic products. Data sourced from EU COSING, US FDA, Health Canada, MHLW Japan, MFDS Korea, ASEAN ACD, GCC SFDA, TGA Australia, ANVISA Brazil, EAEU TR CU, and Taiwan TFDA.